Indegene Reports 39.6% Revenue Growth in Q2FY27

Q2FY27 Revenue: Rs 1,122 Cr | Q2FY27 Net Profit: Rs 112 Cr

Reader Takeaway: Strong revenue expansion led by GenAI adoption faces short-term margin pressure from wage hikes and execution risks.

What just happened

Indegene delivered a strong top-line performance for the quarter ended Q2FY27. The company reported revenue of Rs 1,122 crore, a significant 39.6% increase compared to the previous year. Net profit grew by 10% YoY to Rs 112 crore, although there was a slight sequential decline of 3.4%. EBIT reached Rs 139 crore, reflecting an 18.9% growth over the last year.

Why this matters

The company is successfully scaling its AI-led services, specifically its Tectonic GenAI platform, which saw its revenue run rate jump to US$1.7 million. This shift toward outcome-based, AI-enabled services is driving improved productivity, with revenue per employee rising to US$79,600. The successful conversion of a major pharma pilot into a full-scale engagement signals strong client trust in its digital capabilities.

Management Commentary and Outlook

Management has signaled a stronger H2FY27 compared to H1FY27. The outlook is supported by a robust deal pipeline and a major US$10 million contract expected to peak in Q4FY27. The company remains committed to its goal of achieving 19% EBITDA margins by the end of the fiscal year, relying on operating leverage to offset current cost pressures.

Risks to watch

Investors should monitor margin volatility closely. EBIT margins contracted 216bps YoY, primarily due to wage hikes. Additionally, risks associated with scaling complex AI-led engagements and potential project execution delays remain. High attrition among specialized talent also poses a long-term challenge to maintaining institutional knowledge and client continuity.

What to track next

The focus will be on the execution of the US$10 million contract and whether management can successfully expand margins in the second half of the year as promised.